228 related articles for article (PubMed ID: 1654205)
21. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
22. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
23. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
24. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
25. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
[TBL] [Abstract][Full Text] [Related]
26. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).
Sehested M; Jensen PB; Sørensen BS; Holm B; Friche E; Demant EJ
Biochem Pharmacol; 1993 Aug; 46(3):389-93. PubMed ID: 8394080
[TBL] [Abstract][Full Text] [Related]
27. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
28. ICRF-193, an inhibitor of topoisomerase II, demonstrates that DNA replication in sperm nuclei reconstituted in Xenopus egg extracts does not require chromatin decondensation.
Takasuga Y; Andoh T; Yamashita J; Yagura T
Exp Cell Res; 1995 Apr; 217(2):378-84. PubMed ID: 7698239
[TBL] [Abstract][Full Text] [Related]
29. Chromosome analysis of mouse one-cell androgenones derived from a sperm nucleus exposed to topoisomerase II inhibitors at pre- and post-fertilization stages.
Tateno H; Kamiguchi Y
Mutat Res; 2004 Nov; 556(1-2):117-26. PubMed ID: 15491639
[TBL] [Abstract][Full Text] [Related]
30. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
31. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
33. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast.
Hossain MS; Kurokawa K; Akimitsu N; Sekimizu K
Genes Cells; 2004 Oct; 9(10):905-17. PubMed ID: 15461662
[TBL] [Abstract][Full Text] [Related]
35. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
36. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
38. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
39. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
